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BaCKgRoUND aND aIMS: Several major factors limit 
our understanding of hepatocellular carcinoma (HCC). First, 
human HCCs are infrequently biopsied for diagnosis and thus 
are not often biologically interrogated. Second, HCC initia-
tion and progression are strongly influenced by the cirrhotic 
microenvironment, and the exact contributions of intrinsic 
and extrinsic tumor factors are unclear. A powerful approach 
to examine the personalized biology of liver cancers and the 
influence of host tissues is with patient-derived xenograft 
(PDX) models. In Asia, HCCs from patients with hepatitis 
B virus have been efficiently converted into PDXs, but few 
parallel efforts from the west have been reported.
appRoaCH aND ReSUltS: In a large-scale analysis, 
we implanted 93 HCCs and 8 cholangiocarcinomas (CCAs) 
to systematically analyze host factors and to define an op-
timized platform for PDX development from both surgical 
and biopsy samples. NOD Scid IL-2Rγ−/− (NSG) mice that 
had undergone partial hepatectomy (PHx) represented the 
best combination of engraftability, growth, and passageability, 
but overall rates were low and indicative of a unique intrinsic 
biology for HCCs in the United States. PDX models pre-
served the histology and genetic features of parental tumors, 
and ultimately, eight models were usable for preclinical stud-
ies. Intriguingly, HCC PDXs were differentially sensitive to 
regorafenib and sorafenib, and CCA PDXs were also highly 
sensitive to regorafenib.
CoNClUSIoNS: PDX models functionalize early and 
advanced stage HCCs and revealed unique biological fea-
tures of liver cancers from the United States. (Hepatology 
2020;72:1085-1101).
Hepatocellular carcinoma (HCC) is the sixth most common cancer and second leading cause of cancer-related death worldwide.(1) 
In the United States, its incidence has doubled over 
the past two decades due to the growing number of 
patients with advanced hepatitis C virus (HCV) infec-
tions and/or nonalcoholic steatohepatitis (NASH).(2,3) 
Patients with cirrhosis are at high risk for HCC with 
a 3%-8% annual incidence rate.(4) Once HCC is diag-
nosed, the Barcelona Clinic Liver Cancer (BCLC) 
staging classification divides patients into five stages: 
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0, A, B, C, and D. Stages 0 and A (very early and early) 
are curable by surgical resection, liver transplantation, 
or local ablative therapies.(4) However, a minority of 
patients with HCC are diagnosed with early-stage 
tumors; most patients with HCC present with inter-
mediate or advanced-stage disease, when only pal-
liative therapies are available. Although patients 
diagnosed with early-stage tumors can achieve 5-year 
survival rates exceeding 70% with curative therapies, 
patients with non-early-stage HCC continue to have 
median survival rates of 1-2  years despite the intro-
duction of novel therapies.
Historically, the diagnosis of HCC is often made 
radiographically, without the need for histologic 
confirmation. As a result, most of the characterized 
HCC tissue is from surgical specimens obtained from 
early-stage HCC. This lack of available tissue from 
patients with intermediate-stage or advanced-stage 
HCC has led to a dearth of biological knowledge 
about non-early-stage HCC and likely contributes to 
slow improvements in palliative therapies over time. 
It is unknown whether intermediate and advanced 
HCC represent simple progression from early cases 
or whether these HCC populations consist of distinct 
biological entities with unique growth mechanisms, 
genetic dependencies, and differential sensitivity to 
systemic therapies.
One way to study the growth dynamics and treat-
ment responses of living tumors is with patient- 
derived xenograft (PDX) models. For HCC, there are 
only a few published experiences with PDX models, 
most of which are derived from Asian patients with 
noncirrhotic HBV who underwent curative resec-
tion.(5-8) Although many Asian patients infected 
with HBV develop HCC in the absence of cirrhosis, 
over 90% of U.S. and European patients with HCV, 
alcohol, and NASH develop HCC in the presence 
of cirrhosis.(9) Thus, prior PDX models may not be 
entirely representative of HCCs from the Western 
world.
In this study, we have established methodologies 
for PDX development for a large number of U.S. 
patients with cirrhosis and HCC. Engraftment and 
passageability rates for HCCs are low, but optimized 
recipient protocols can increase efficiency. We also 
found that HCC biopsies can generate PDX models. 
These HCC PDXs help to characterize the biology of 
HCC in the Western world and represent an import-
ant resource for future studies. This knowledge will 
help elucidate mechanisms of response to available 
and experimental therapeutics.
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Highlights
• We present a U.S. liver cancer PDX biobank from surgical 
and biopsy cases.
• Human HCC engraftment in mice increased with greater 
immunodeficiency and liver injury.
• The frequency and rate of engraftment is low, indicative of 
unique biological features of HCCs.
• These patient avatars show that there are differential sensi-
tivities to sorafenib and regorafenib reflecting heterogeneous 
responses seen in the clinic.




All mice were handled in accordance with the 
guidelines of the Institutional Animal Care and Use 
Committee at the University of Texas Southwestern 
(UTSW) Medical Center. NSG mice were from 
the UTSW breeding core, and FRG mice were from 
Yecuris Corporation (strain 10-0001). All experiments 
were done in 6-10-week-old male and female mice. 
All experiments were done in an age-controlled and 
sex-controlled fashion unless otherwise noted.
HUMaN SaMpleS
HCC and CCA tumor samples were obtained from 
patients who underwent surgical resection or percuta-
neous biopsies. All patients provided informed consent 
under internal review board #STU 062013-063 for 
liver tissues and #STU 092013-010 for blood sam-
ples. Pathologic diagnosis was confirmed by a board- 
certified pathologist specializing in gastrointestinal 
oncology (P.G.) in a blinded fashion. A total of 101 
tumor samples were implanted. Patients had an average 
age of 62 years old (77 males, 24 females).
IMplaNtatIoN oF tUMoRS  
INto ReCIpIeNt MICe
For SQ experiments, multiple tumor fragments of 
2-5 mm3 were implanted with or without PHx. For 
liver implantation, an incision was made in the abdo-
men, and a fragment (1-2  mm3) was implanted and 
sealed with a small piece of Surgicel to stop bleed-
ing. For FRG mice, NTBC water was removed after 
the surgery and cycled every 7 to 10  days to induce 
liver injury. Mice implanted with parental tumors 
were euthanized before any tumor grew to 2  cm in 
diameter. Tumor growth in liver was examined at the 
time of euthanasia. To expand a PDX model, tumors 
were implanted to multiple NSG mice without PHx, 
snap frozen for future data analysis, fixed with 4% 
paraformaldehyde for histology, and stocked in 10% 
DMSO  +  90% FBS for future use. Some xenografts 
were thawed from frozen stocks and re-implanted 
into NSG mice subcutaneously. After thawing and 
implanting, mice were maintained the same way as 
primary xenograft implantation.
HIStology
Tissue samples were fixed in 4% paraformaldehyde 
and paraffin embedded. Primary antibodies used were 
Hep Par1 (OCH1E5) (264M-94; Sigma-Aldrich, 
St. Louis, MO), EpCAM (#14452; Cell Signaling, 
Danvers, MA), CK19 (ab15463; Abcam, Cambridge, 
United Kingdom), CD31 (ab28364; Abcam), CD45 
(ab10558; Abcam), and Ki-67 (ab15580; Abcam). 
Detection was performed with the Elite ABC Kit and 
DAB Substrate (Vector Laboratories, Burlingame, 
CA), followed by hematoxylin counterstaining (Vector 
Laboratories).
RNa eXtRaCtIoN aND 
QUaNtItatIVe Real-tIMe pCR
Total RNA was extracted from tumors and corre-
sponding xenografts using the Invitrogen PureLink 
RNA mini kit (Carlsbad, CA). Complementary DNA 
was synthesized using iScript reverse-transcription 
reagents (Bio-Rad Laboratories, Hercules, CA). Human 
or mouse gene expression was detected using human 
or mouse-specific primers. A common glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) primer set, 
which reacts with both human and mouse GAPDH, 
was used as reference gene. Expression level was nor-
malized to human or mouse sample controls.
DRUg StUDIeS WItH pDX 
MoDelS
Tumor fragments (125  mm3) were implanted in 
both flanks of 10 NSG mice, with 5 mice for each 
group. Treatment was initiated when the tumor 
volume reached approximately 50  to  200  mm3. 
Sorafenib and Regorafenib were purchased from LC 
Laboratories (Woburn, MA). Sorafenib was dissolved 
with Cremophor EL : ethanol (1:1) for stock and 
diluted 4-fold with water just before use.(10) Sorafenib 
(10 mg/kg) was given by oral gavage once a day, and 
control mice were given diluted vehicle. Regorafenib 
was dissolved in DMSO at 100  mg/mL for stock 
solution and then diluted using 1:1 mixture of PEG 
300 and 30% captisol.(11) Mice were gavaged once 
daily with regorafenib (20 mg/kg) or vehicle. Long 
(L) and short diameters (S) were measured for each 
tumor twice a week. Tumor volume was calculated by 
V = 1/2*L*S2.
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FIg. 1. PDX engraftment in immunodeficient recipients with and without liver injuries. (A) Schema of procedure. (B) Representative 
pictures of tumors engrafted. (C) Engraftment frequency in the SQ space or the liver in different types of immunodeficient murine 
recipients. (D) Engraftment time of PDXs in different recipients. Fisher’s exact tests were used to compare engraftment times. (E) Overall 
engraftment time of PDXs in all types of recipients. (F) The number of PDX models that engrafted within 5 months in NSG mice plus 
hepatectomy versus nonresected NSG mice. Fisher’s exact test was used for statistical analysis.
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WHole-eXoMe SeQUeNCINg, 
pRoCeSSINg, aND MUtatIoN 
CallINg
Genome DNA was extracted from parental tumors 
and corresponding xenografts using the Qiagen all-prep 
DNA/RNA mini kit (Hilden, Germany). DNA was 
submitted to Admera Health (South Plainfield, NJ) for 
whole-exome sequencing. We used the QBRC pipe-
line (github.com/Somat ic-pipel ine/QBRC-Somat ic- 
Pipeline) for somatic mutation calling. Exome-
seq reads were aligned to the GRCh38 genome by 
BWA-MEM.(12) Picard was used to add read-group 
information, and sambamba was used to mark PCR 
duplicates. The calculation of read coverage is per-
formed after duplicate removal. A genome anal-
ysis toolkit (GATK)(13-15) was used to perform 
base-quality score recalibration and local realignment 
around Indels. MuTect,(16) VarScan,(17) Shimmer,(18) 
SpeedSeq,(19) Manta,(20) and Strelka2(21) were used 
to call single-nucleotide polymorphisms (SNPs) and 
indels. A mutation called by 3 or more of any of these 
algorithms was retained. ANNOVAR was used to 
annotate SNPs and indels.(22) All SNPs and indels 
were combined and kept only if there were at least 
seven total (wild-type and variant) reads in the blood 
normal sample and at least three variant reads in the 
parental tumor or xenograft sample. Only mutations 
found in COSMIC (https://cancer.sanger.ac.uk/ 
cosmic) were kept. The visualization of mutations by 
oncoplot is generated by the function oncoplot in R 
package maftools.
RNa-Seq aND Data aNalySIS
Total RNA was extracted from tumors using 
the Invitrogen PureLink RNA mini kit. Libraries 
were prepared with the Ovation RNA-Seq Systems 
1-16 (NuGEN Technologies, San Carlos, CA), and 
indexed libraries were multiplexed in a single-flow 
cell and underwent 75 base pair single-end sequenc-
ing on an Illumina NextSeq500 (San Diego, CA) 
using the High Output kit v2 (75 cycles) at the 
UTSW Children’s Research Institute Sequencing 
Facility. To compare RNA expression between 
parental tumor samples that engrafted versus did 
not engraft, RNA was extracted and submitted 
to Admera Health for paired-end RNA-seq. The 
sequence reads were aligned to the GRCm38 with 
STAR.(23,24) Read counts were generated for the 
annotated genes by featureCounts.(25,26) Differential 
gene analysis was performed use edgeR, with a false 
discovery rate of less than 0.05 as the cutoff.(27,28) 
Heatmaps to visualize the data were generated 
using the R heat.map2 package. GSEA analysis was 
performed with a preranked gene list by log fold 
change.(29) PCA analysis was performed using the 
R prcomp function.
StatIStICal aNalySIS
The data in most figures reflect multiple exper-
iments performed on different days using mice 
from different litters. Two-tailed Student t tests 
(two-sample equal variance) were used to test the 
taBle 1. engraftment of liver-Cancer pDX Models in Different locations and Recipients
Recipients Route Implanted
HCC/CCA PDXs Engraftment Time Passageable Lines
Amount Percentage Weeks Amount Percentage
NSG SQ 42 6 14.3% 27.3
Liver 27 4 14.8% 22.9
Overall 44 9 20.5% 27.9 1 2.3%
FRG SQ 14 1 7.1% 13.3
Liver 14 4 28.6% 28.7
Overall 14 5 35.7% 25.6 1 7.1%
NSG + PHx SQ 43 7 16.3% 14.4*
Liver 43 3 9.3% 26.3
Overall 43 9 20.9% 19.5 7 16.3%
Total 101 23 22.8% 24 9 8.9%
*P = 0.025 when compared with the NSG-SQ group.
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significance of differences between two groups. 
Fisher’s exact tests and Mann-Whitney U tests were 
used where specifically indicated. In all figures, sta-
tistical significance is represented as mean  ±  SEM 
(*P  < 0.05, **P  < 0.01, ***P  < 0.001, †P  < 0.05, and 
‡P < 0.01).
Results
HCCs eNgRaFt at loW RateS 
IN IMMUNoDeFICIeNt MICe 
WItHoUt lIVeR DaMage
First, we implanted fresh surgical liver tumor 
specimens in the subcutaneous (SQ) space of NOD 
Scid IL-2Rγ−/− (NSG) mice (Fig. 1A). NSG mice 
were selected because they are the most immunode-
ficient mice available. We quantified tumor engraft-
ment defined as growth (at any anatomical location) 
to greater than 5 mm in diameter within 12 months 
(Fig. 1B). For SQ implantation, the engraftment rate 
was 14.3% (6 of 42 cases; see Table 1 and Fig. 1C), 
and the engraftment time was 27.3 weeks (Fig. 1D). 
Interestingly, in four of these six cases, engraftment 
was in the form of metastasis to the liver without 
detectable growth of tumors in the SQ space (Fig. 1B 
and Supporting Table S1).
Given the long times and low engraftment 
rates, we aimed to determine what factors influ-
ence engraftment, growth rates, and passageability 
of liver-cancer PDX models. The SQ approach is 
convenient to assess for engraftment because one 
can visualize and palpate for tumor growth, but it 
is possible that the skin microenvironment was sub-
optimal for liver-cancer engraftment. Because there 
are likely local pro-growth signals emanating from 
normal to malignant liver tissues, we also implanted 
tumors in normal, undamaged NSG livers using an 
orthograft approach. When tumors were implanted 
in the liver, the engraftment rate was 14.8% (4 of 
27 cases), although this was more challenging to 
assess because laparotomy was not used to detect 
early-stage PDX tumors before terminal liver har-
vesting. The average engraftment time in liver was 
22.9  weeks, but this time reduction (compared to 
27.3  weeks for SQ) was not statistically significant 
(Fig. 1D). Another caveat is that it was more diffi-
cult to implant larger or multiple tumor fragments 
within the liver due to tissue fragility and bleeding 
risk. Thus, orthografting into the liver is inherently 
less efficient.
The overall engraftment rate for either SQ or liver 
implantation was 20.5% (9 of 44 cases), and the aver-
age engraftment time was 27.9  weeks (Table 1 and 
Fig. 1E). Surprisingly, the growth of tumors often 
FIg. 2. Comparison of PDX engraftment in surgical versus biopsy samples. (A) Engraftment frequency of PDXs in surgical versus biopsy 
samples of patients with HCC. (B) Engraftment frequency of PDXs in surgical versus biopsy samples of patients with HCC (n = 17, 
n = 3). Fisher’s exact test was used for (A). Abbreviation: n.s., not significant.
A B
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took more than 5  months (27  weeks), making these 
challenging tumor models to develop (Fig. 1E,F). 
This likely reflected the slow-growth biology of 
human HCCs and is consistent with the dou-
bling time of HCCs, which has been reported to be 
6-12 months.(30)
FIg. 3. The serial passageability of liver-cancer PDX models. (A) This shows the passageability of PDXs generated in three types 
of recipients. Fisher’s exact test was used for statistical analysis. (B) Time required for each PDX model to engraft and passage. Once 
engrafted, tumors were passaged into additional NSG mice to expand the PDX lines. HCC-HS84 was generated from NSG mice. HCC-
HS119 was generated from FRG mice. All other lines were generated from NSG mice that had undergone PHx. (C) Engraftment time 
for frozen and thawed PDX tumors. CCA-HS127, CCA-HS131, HCC-HS84, HCC-HS119, HCC-HS157, CCA-HB163 and HCC-
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FIg. 4. PDXs maintain the features of parental tumor histology. (A) H&E staining of parental tumors and passaged PDX lines. Scale 
bar = 100 μm. (B) Immunohistochemistry staining of parental tumor samples and PDXs with anti-Hep Par1, anti-EpCAM, and anti-
CK19 antibodies. Scale bar = 100 μm. (C) H&E staining showed that thawed PDXs have a similar histology as the primary PDX and 
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pDX eNgRaFtMeNt IS eNHaNCeD 
WItH geNetIC aND SURgICally 
INDUCeD lIVeR INJURIeS
Because liver cancer often arises in the context of 
diseased liver tissues, we hypothesized that the host 
environment would be a critical variable. A tumor 
microenvironment that integrates liver injury, inflam-
mation, and regeneration might accelerate PDX 
growth. We attempted to transplant tumors into 
a mouse model with chronic liver damage caused 
by hereditary tyrosinemia.(31) Due to a defect in an 
enzyme involved in tyrosine metabolism, the liv-
ers of Fumarylacetoacetate hydrolase (Fah)−/−; Rag1−/−; 
IL-2Rγ−/− (FRG) mice accumulate a toxic metabolite 
called fumarylacetoacetate and die from liver failure 
within 2-4 months. To effectively treat this liver dis-
ease, mice and human patients are normally given 
nitisilone or NTBC (2-[2-nitro-4-trifluoromethyl-
benzoyl]-1,3-cyclohexanedione), a drug that clears 
fumarylacetoacetate and maintains a healthy liver.(31) 
If kept alive for over 6 months on intermittent treat-
ment, Fah knockout mice can develop cirrhosis and 
HCC,(32) indicating that these mice can support the 
growth of endogenous liver cancers.
Fourteen human liver tumors were transplanted 
into FRG mice, then NTBC was withdrawn and 
cycled (see Methods) to induce liver damage in the 
host livers. Tumors were simultaneously implanted 
in the liver and SQ space of the individual FRG 
mice. Among the 14 cases, five engrafted (four in 
the liver and one in the SQ space; see Table 1). This 
increased the engraftment rate in liver from 14.8% 
to 28.6%, suggesting that the damaged liver micro-
environment could promote HCC engraftment in 
the liver (Fig. 1C). Improvements in overall engraft-
ment frequency between FRG and NSG (35.7% 
vs. 20.5%) was not accompanied by a significantly 
shortened engraftment time (25.6 vs. 27.0  weeks) 
(Table 1 and Fig. 1E). The specific engraftment 
frequency of SQ tumors was lower in the FRG 
versus NSG mice (7.1% vs. 14.3%) (Fig. 1C), sug-
gesting that pro-cancer microenvironmental factors 
were acting locally and not through the systemic 
circulation.
Importantly, we learned that an orthograft 
approach in FRG could increase PDX-engraftment 
frequency but did not shorten engraftment time. We 
reasoned that the deeper immunodeficiency of NSG 
as compared with FRG could have provided an 
important benefit. Because it would be difficult to 
make FRG more immunodeficient, we asked whether 
introducing liver damage to NSG would allow us 
to synergize the deeper immunodeficiency of NSG 
with the liver injury associated with FRG. We stim-
ulated regeneration in NSG mice by performing a 
40% partial hepatectomy (PHx) of the left lateral 
lobe at the time of liver tumor implantation. This is 
a less aggressive surgery than the standard 60%-70% 
PHx, but can be more easily performed and allows 
for a higher survival rate. For 43 patient cases, we 
implanted liver tumors into both SQ and liver loca-
tions in each mouse subjected to PHx. Seven of 43 
tumors engrafted in the SQ space (16.3%) and 4 of 
43 cases engrafted in the liver (9.3%). Two of these 
cases overlapped, thus resulting in a total of 9 of 
43 cases that engrafted (20.9%) (Table 1 and Fig. 
1C). Although the engraftment frequency did not 
increase substantially for either SQ or liver implan-
tations, the engraftment time for SQ cases sig-
nificantly decreased to 14.4  weeks compared with 
27.3  weeks for NSG implantations without hepa-
tectomy (P value = 0.025; Fig. 1D). Seven of the 9 
PDX lines generated in NSG mice with hepatectomy 
engrafted in less than 5  months, whereas only one 
of nine generated in the NSG mice without surgical 
resection engrafted in less than 5 months (Fig. 1F). 
As mentioned previously, FRG did not shorten the 
time to engraftment. Overall, SQ implantation into 
NSG mice with PHx provided the most advantages 
in terms of speed and (as will be discussed subse-
quently) serial passageability of PDX models.
pDX MoDelS CaN alSo Be 
geNeRateD FRoM lIVeR 
CaNCeR BIopSIeS
Some patients do not undergo surgery due to met-
astatic disease or poor functional status but many 
have undergone biopsy as part of their diagnostic 
workup. Patients with advanced HCCs could benefit 
from PDX models that reveal therapeutic sensitivities. 
Because biopsies are derived from advanced BCLC–
stage HCCs, we hypothesized that these could har-
bor more aggressive cancer cells that would increase 
engraftment and PDX growth. To address this, we ana-
lyzed the cases in which we implanted biopsy-derived 
tissues into the various recipient models described 
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previously. Seventeen of 69 HCC surgical samples 
(24.6%) and 3 of 24 HCC biopsy samples (12.5%) 
resulted in engraftment (Fig. 2A and Supporting 
Table S2). For biopsies, there was not a significant 
difference in engraftment frequency in different recip-
ient types, potentially due to low case numbers. The 
average engraftment time was also similar for surgi-
cal and biopsy samples (Fig. 2B). Taken together, the 
data did not support the hypothesis that biopsy cases 
from advanced HCCs display a more aggressive biol-
ogy that can be detected in a PDX assay. As a caveat, 
the reduced mass of biopsy versus surgically derived 
tissues could have suppressed engraftment efficiency. 
We also implanted six surgical and two biopsies from 
patients with CCA. Two of the surgical and one of 
the biopsy samples engrafted (Supporting Table S2), 
hinting at an overall higher engraftment rate for 
CCA versus HCC, regardless of whether the tissue 
came from a surgery or biopsy. What is clear is that 
biopsy samples from patients with liver cancer can 
engraft into useful PDX models. Overall, 23 of 101 
(22.8%) primary liver cancers obtained through sur-
gery or biopsy grew macroscopically in the primary 
PDX transplant setting within 12 months.
A B
C D
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pDXs CaN Be paSSageD, FRoZeN, 
tHaWeD, aND eXpaNDeD
For PDX models to be useful for future studies, 
they not only had to grow in the primary transplant 
setting, but they needed to be serially passageable. To 
determine this, we re-implanted fragments of the liver 
tumor to additional NSG mice without PHx to deter-
mine whether they could be passaged and how many 
passages could be sustained. Many PDXs, even if they 
engrafted initially, did not grow after subsequent pas-
saging. In nine PDX lines that engrafted in uninjured 
NSG mice, only one could be serially transplanted 
(11.1%). In the five lines that engrafted in FRG mice, 
one could be serially transplanted (20%). However, in 
the nine lines that engrafted in NSG  +  PHx mice, 
seven could be serially transplanted (Fig. 3A) (78%). 
Thus, host liver resection/regeneration was associated 
with increased passageability of the PDX lines. The 
biological mechanisms are unknown, but our data 
suggested that local or circulating regeneration fac-
tors might select for tumor clones that are serially 
transplantable. Out of the 23 PDXs that engrafted, 
15 could be passaged at least once, and nine could be 
passaged more than 3 to 4 times (Fig. 3B). Six of the 
15 stopped growing after two to three passages. For all 
passages, we collected and snap froze PDX fragments 
(~125 mm3) in 10% DMSO/90% fetal bovine serum 
(FBS) to bank tumor stocks. Seven of the lines could 
be thawed and re-implanted successfully. These lines 
include HCC-HS84, HCC-HS119, CCA-HS127, 
CCA-HS131, HCC-HS157, CCA-HB163, and 
HCC-HB179 (Fig. 3C). HCC-HS141 could not be 
successfully thawed but the primary tumor has been 
passaged for more than 6 times. Altogether, we have 
FIg. 5. HCC PDXs retain the genomic expression and mutational profiles of parental tumors. (A) PCA analysis of RNA-seq data from 
seven pairs of parental tumors and PDX samples. HS57, HS84, HS119, HS141, and HS157 are histological HCCs. HS127 and HS131 
are CCAs. (B) Clustering of samples based on evaluation of highly expressed genes in liver cancer. (C) Whole-exome sequencing in 
parental tumors and PDX models. (D) Oncoplot of mutations in parental tumors and PDXs. We focused on 35 commonly mutated genes 
in liver cancer based on the The Cancer Genome Atlas analysis. COSMIC mutations or exome mutations compared with 1,000 genomes 
are shown. Abbreviations: ACVR2A, activin A receptor type 2A; AFP, alpha fetoprotein; ALB, ALBUMIN; AKR1B10, aldo-keto 
reductase family 1 member B10; ANLN, anillin actin binding protein; ARID1A, AT-rich interaction domain 1A; BTNL8, butyrophilin 
like 8; BUB1, BUB1 mitotic checkpoint serine/threonine kinase; CCNB1, cyclin B1; CCND1, cyclin D1; CDKN2A, cyclin dependent 
kinase inhibitor 2A; CENPA, centromere protein A; CENPQ, centromere protein Q; CREB3L3, cAMP responsive element binding 
protein 3 like 3; CSMD1, CUB and Sushi multiple domains 1; CTNNB1, catenin beta 1; DHRS2, dehydrogenase/reductase 2; E2F8, 
E2F transcription factor 8; EEF1A1, eukaryotic translation elongation factor 1 alpha 1; ERRFI1, ERBB receptor feedback inhibitor 1; 
EPCAM, epithelial cell adhesion molecule; FER1L6, fer-1 like family member 6; GMNN, geminin DNA replication inhibitor; G6PD, 
glucose-6-phosphate dehydrogenase; GPC3, glypican 3; GPR158, G protein-coupled receptor 158; HIST1H1B, H1.5 linker histone, 
cluster member; KEAP1, kelch like ECH associated protein 1; LCN2, lipocalin 2; LZTR1, leucine zipper like transcription regulator 
1; MDK, midkine; NFE2L2, nuclear factor, erythroid 2 like 2; NT5DC2, 5'-nucleotidase domain containing 2; PDZK1IP1, PDZK1 
interacting protein 1; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PLVAP, plasmalemma vesicle 
associated protein; PTEN, phosphatase and tensin homolog; PTP4A3, protein tyrosine phosphatase 4A3; PTTG1, PTTG1 regulator of 
sister chromatid separation, securing; RP1L1, RP1 like 1; T, tumor; TG, tumor graft; TP53, tumor protein p53.
FIg. 6. Comparison of tumors that did and did not engraft in the PDX assays. Representative images of Ki-67 staining of patient tumors 
that did and did not engraft (left). Scale bar = 100 μm. Statistical analysis of Ki-67-positive cells (right, n = 20, n = 37). Abbreviation: n.s., 
not significant.
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generated eight PDX lines that can be thawed from 
frozen stocks or maintained as live tumors in mice. In 
summary, NSG mice undergoing PHx are the opti-
mal hosts for HCC PDX models because of increased 
engraftment rate, reduced engraftment time, and 
increased serial passageability after freeze–thaw cycles.
pDXs MaINtaIN paReNtal 
tUMoR FeatUReS at 
tHe HIStologIC aND 
tRaNSCRIptoMIC leVelS
Tumor architecture, histology, growth, and invasive-
ness of PDX models and their corresponding primary 
tumors were compared. To confirm the human ori-
gin of these PDX tumors, we performed quantitative 
real-time PCR to show that the PDX lines expressed 
human rather than mouse genes. We found that eight 
originated from human cells (Supporting Fig. S1). 
We compared the histology of these eight lines with 
their parental tumors. Hematoxylin and eosin (H&E) 
staining for PDXs harvested after different passages 
showed that PDXs and parental tumors were mini-
mally changed over time (Fig. 4A and Supporting 
Fig. S2A,C). Clusters of differentiation (CD) 45 
staining was used to identify and exclude PDXs that 
resembled lymphomas (data not shown). Eight pairs 
of PDXs and parental tumors were stained with 
FIg. 7. Differential sensitivity of HCC and CCA-PDX lines to sorafenib and regorafenib. (A,C,E,G) HCC or CCA PDX lines treated 
with sorafenib (n = 5 to n = 10). (B,D,F,H,I) HCC or CCA PDX lines treated with regorafenib (n = 5 to n = 10). Two-tailed Student 
t tests were used to determine statistical differences between treatments at the same individual time points (shown by asterisks), and 
Mann-Whitney U tests were used to identify statistical differences between growth curves (shown by cross).
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Hep Par1, EpCAM (epithelial cell adhesion mole-
cule), and CK19 (cytokeratin 19), markers of hepatic 
and biliary differentiation. HCC PDXs and primary 
HCCs expressed the same levels of these markers. As 
expected, CCA cases were Hep Par1–negative and 
CK19-positive. Representative images are shown in 
Fig. 4B and Supporting Fig. S2B,D. PDX histology 
was also maintained after thawing and passaging, 
making it possible to use the PDX models for future 
studies (Fig. 4C and Supporting Fig. S2A,C).
Whole-exome and RNA-sequencing (RNA-seq) 
was used to determine whether mutation and expres-
sion signatures were preserved. This kind of analysis, 
along with histologic evaluation, can help to determine 
whether key features of the original cancer are retained. 
Principal component analysis (PCA) analysis was not 
able to separate the RNA-seq transcriptomes of seven 
pairs of tumor and PDX from the same patient (Fig. 
5A). Clustering based on highly expressed genes in 
liver cancer resulted in the pairing of PDXs with their 
corresponding parental tumors (Fig. 5B). Whole-
exome sequencing analysis also showed that most 
mutations were retained in the PDXs when compared 
with parental tumors (Fig. 5C). HCC driver muta-
tions were also frequently shared by PDXs and patient 
tumors (Fig. 5D).
ClINICal oR geNetIC 
FeatUReS CoUlD Not pReDICt 
eNgRaFtMeNt oF tUMoR 
tISSUeS
We aimed to determine whether clinical vari-
ables such as tumor differentiation correlated with 
FIg. 8. Effect of regorafenib and sorafenib on angiogenesis and cell proliferation in PDX models. (A) Representative images of H&E, 
angiogenesis (CD31), and proliferation (Ki-67) of HCC-HS84 PDX treated with sorafenib or regorafenib (left). Statistical analysis of 
CD31-positive area and Ki-67-positive cells (right). Scale bar = 100 μm. (B) Representative images of H&E, angiogenesis (CD31), and 
proliferation (Ki-67) of HCC-HS157 PDX treated with sorafenib or regorafenib (left). Statistical analysis of CD31-positive area and 
Ki-67-positive cells (right). Scale bar = 100 μm. Abbreviation: n.s., not significant.
A
B
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engraftment. Among 69 surgical HCC cases, 43 
cases were moderately differentiated, and nine of 
these successfully engrafted (21%; see Supporting 
Table S2). Seventeen were poorly differentiated, and 
five engrafted (29%). When comparing the engraft-
ment for “moderate,” “moderate to poor,” and “poor” 
HCCs, there was a nonsignificant trend of increas-
ing engraftment from 21% to 25% to 29%. However, 
3 of 17 poorly differentiated HCCs were serially 
transplantable, whereas 0 of 43 moderately differ-
entiated HCCs were transplantable (Supporting 
Table S2; Fisher’s exact test; P = 0.02). Surprisingly, 
the well-differentiated HCC samples could also 
engraft, although the number of cases was not high 
enough to evaluate the engraftment rate. Previous 
reports of Asian HCC PDX models showed that 
engraftment correlated with tumor cell prolifer-
ation as measured by Ki-67. In our cohort, Ki-67 
staining on 20 engrafting and 37 nonengrafting 
primary tumors showed no significant differences 
in the frequency of Ki-67-positive cells (Fig. 6). To 
determine whether we could identify transcriptomic 
predictors of engraftment, we also performed deep 
RNA-seq on cohorts of parental tumors that either 
did or did not engraft in PDX assays (n = 17 and n = 
19). However, we did not identify gene sets that 
could reliably distinguish between engrafting and 
nonengrafting cases using a combination of gene 
set enrichment analysis (GSEA) and logistic regres-
sion analyses with lasso regularization and elastic 
net regularization. In addition, clinical features such 
as alanine aminotransferase, aspartate aminotrans-
ferase, and other serum markers could not predict 
engraftment (data not shown).
pDX MoDelS SHoW 
DIFFeReNtIal SeNSItIVIty to 
SoRaFeNIB aND RegoRaFeNIB
We sought to ask whether liver-cancer PDXs 
could help define therapeutic sensitivities of treat-
ments used in the clinic. Recently, the number of 
first-line and second-line systemic treatment options 
for advanced HCC has increased to include four 
multikinase inhibitors and two PD-1 inhibitors, and 
it has not been clear how to choose which therapy 
and in which order. Here, we used our PDX models 
to serve as patient avatars for the choice between 
the first-line and second-line HCC multikinase 
inhibitors sorafenib and regorafenib. For sorafenib, 
two of three HCC PDX models (HCC-HS84, 
HCC-HS141, and HCC-HS157) showed a sub-
stantial response and one did not (Fig. 7A,C,G), 
indicating that these models can help to discern 
sorafenib sensitivity. A CCA-PDX model showed 
no response to sorafenib, as would be expected (Fig. 
7E). The same PDX models were tested with rego-
rafenib, which is approved for second-line HCC 
treatment in patients who progress on sorafenib.(33) 
More of these models showed sensitivity to rego-
rafenib, but one of the four HCC models was only 
modestly sensitive (Fig. 7B,D,H). This indicates 
that regorafenib could have a higher response rate 
in the first-line setting and may be appropriate 
for treatment-naive as well as sorafenib-resistant 
patients. The most surprising result was that the 
CCA-PDX model was exquisitely sensitive to rego-
rafenib, which was previously unknown (Fig. 7F,I).
We also performed histological and molecular 
analyses of treated versus untreated PDX tumors in 
an effort to reveal mechanisms by which sorafenib or 
regorafenib could impede tumorigenesis. We measured 
the anti-angiogenesis effects by using immunohisto-
chemistry of CD31, which is an endothelial marker 
that allows us to quantify vessels, and we measured 
proliferation using Ki-67 (Fig. 8). Both drugs had an 
effect on proliferation, but regorafenib had a more pro-
nounced effect in both PDX lines. Although sorafenib 
did not have a significant effect on vascular density 
as measured by CD31, regorafenib had a significant 
effect in the HCC-HS84 PDX line. Thus, these drugs 
have a different magnitude of anti-angiogenesis and 
antiproliferative effects in different lines, and this can 
partially explain the sensitivity of each line.
Discussion
PDX models have the potential to uncover new bio-
logical information about individual patient-derived 
liver tumors that have not been adulterated by pro-
longed growth on plastic under artificial nutrient con-
ditions. Our goal was to understand tumor intrinsic and 
extrinsic features that would affect tumor biology using 
PDX engraftment, growth, and passageability as in 
in vivo assays. We first attempted to pinpoint the tumor 
extrinsic host factors that regulate liver cancer growth. 
In general, it has been difficult to assess the impact 
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of the tumor microenvironment on clinically relevant 
liver tumor models. Within genetically engineered 
mouse models, it is difficult to isolate tumor intrinsic 
and extrinsic factors. Also, commonly used HCC cell 
lines have been so intensely selected for rapid growth 
that they may not respond to more subtle environmen-
tal cues that would otherwise have a greater impact on 
slower growing tumors. In our experience, it was surpris-
ing that the location of implantation (SQ or liver) did 
not have a major influence on tumor growth. It is pos-
sible that the technical challenges associated with liver 
orthograft implantation disadvantaged that approach 
when compared with SQ implants, which could accom-
modate more transplanted tissue.
Not surprisingly, inducing liver injury in immu-
nodeficient mice could promote tumor growth. It 
is known that tumor initiation is promoted by liver 
damage, but it is less well understood if the growth 
of established tumors is enhanced by liver injury. Our 
data show that even established HCCs can engraft 
and grow more efficiently when liver injury is intro-
duced through genetic liver damage (Fah deletion) 
or surgical resection (PHx). Interestingly, our exper-
iments support a model in which both signals acting 
locally in FRG mice and in circulation in the con-
text of hepatectomized NSG mice could promote 
cancer growth. Deeper immunosuppression was also 
important, as tumors generally grew better in NSG 
as compared with FRG mice. This information about 
non-cell autonomous regulators of HCC growth 
allowed us to optimize our efforts to functionalize 
living tumor tissues. We recommend performing 40% 
PHx to promote growth and long-term passageability 
of HCCs implanted into the SQ space of NSG mice.
In regard to comparing host models, there are 
limitations to our study that need to be highlighted. 
Because of time constraints that occur after clinical 
liver resections, we were not able to implant primary 
patient tumor tissues into the three different host 
mouse models at the same time. Each host model 
requires 3-5 mice, which is why performing 10-15 
surgeries at the end of the clinical workday was 
not feasible. Instead, our study retrospectively com-
pared the engraftment efficiencies between different 
hosts; therefore, we cannot say that for each patient, 
one engraftment approach is definitively better than 
another. However, we did implant two established 
PDX models into all three of the hosts and we found 
that PHx could modestly improve the growth of one 
of the models within the liver as compared with FRG 
or no PHx (Supporting Fig. S3). Although this indi-
cates that PHx is likely to be an important instiga-
tor of engraftment or growth, this is anecdotal data. 
Another caveat is that we cannot exclude the effects 
of the surgical procedure itself when we perform PHx 
in NSG mice. Sham operations without PHx would 
have provided better controls. Despite these limita-
tions, we believe that there is robust evidence that 
liver injury exemplified by PHx can promote PDX 
engraftment in heavily immunosuppressed mice.
There were also tumor-intrinsic features of the 
HCCs that influenced PDX growth. A study by Gu 
et al. showed that more than 60 viable HCC-PDX 
models have been generated from Chinese patients. 
These PDXs readily engraft, grow, and are used for 
drug studies.(7) Interestingly, our experience with U.S. 
patients did not mirror that study, despite implant-
ing over 100 patient cases. In general, engraftment 
frequency, growth rates, and passageability were very 
low in comparison to the Asian studies. We are con-
fident that there were no technical issues impairing 
PDX engraftment, as our group has also generated 30 
gastric cancer PDX models from 70 implanted (43% 
success rate, unpublished), even considering the fact 
that these PDXs were generated from esophagogas-
troduodenoscopy-derived biopsies that are generally 
more scant in mass and cellularity. Our data suggest 
inherent biological differences among liver cancers 
from different geographic locations, either due to 
genetic background or etiology.
Overall, we implanted 93 HCC samples and eight 
CAA samples in different recipient mice to generate 
PDX models. Our results showed that immune defi-
ciency and liver injury could improve engraftment and 
PDX passageability. Using the PDX lines generated 
with this study, we were able to test the differential 
sensitivity of sorafenib and regorafenib in both HCC 
and CCA PDXs. Furthermore, we also found that 
PDX lines can be generated from surgical samples as 
well as biopsy samples, making it possible to preclini-
cally test drugs for patients with advanced liver cancer. 
In the future, machine learning algorithms could also 
be used to identify potential predictors of engraftment 
and treatment response. We have not yet been able to 
do this because of limited statistical power, but larger 
studies in the future could permit the use of these 
approaches. Our study reports an important experi-
ence in a large number of patients with liver cancer 
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and lays the foundation for future efforts to function-
alize HCCs and CCAs from patients.
Data and Software 
Availability
The sequencing data reported in this paper has 
been deposited into the European Genome-phenome 
Archive (EGA) database. The EGA access ID is 
EGAS00001004020.
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